Aminolevulinic acid photodynamic therapy for folliculitis decalvans: A case report

Lin, Xiangfei; Zhou, Siyu; Wang, Xiaokang; Zhu, Xiaofang

doi:10.1111/dth.13358

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two case reports reported that 3 cycles of MAL-PDT and 4 cycles of ALA-PDT resulted in sustained remission of FD for 1 year without any adjunctive therapy. 165,166 These encouraging findings were corroborated by a prospective study showing that 4 sessions of MAL-PDT resulted in a clinical response for 9/10 patients with FD, with 6 patients exhibiting disease remission, and a retrospective study showing that 9/13 patients with FD undergoing 3 sessions of ALA-PDT were well-controlled with no recurrence at 12 months. 167,168 However, the literature includes some conflicting results, with 1 case series reporting treatment failure for 3 patients with recalcitrant FD treated with a mean number of 11 MAL-PDT sessions.…”

Section: Folliculitis Decalvansmentioning

confidence: 85%

A Review of the Dermatologic Clinical Applications of Topical Photodynamic Therapy

Luo,

Bose,

Bawazir

et al. 2024

J Cutan Med Surg

View full text Add to dashboard Cite

Topical photodynamic therapy is a widely approved therapy for actinic keratoses and low-risk nonmelanoma skin cancers with a rapidly growing range of emerging indications for other cutaneous diseases. This review summarizes the best-available evidence to provide a clinical update for dermatologists on the approved and emerging indications of photodynamic therapy. The body of evidence suggests that photodynamic therapy is superior or noninferior to other available treatment modalities for actinic keratoses, low-risk basal cell carcinomas, Bowen’s disease, skin field cancerization, chemoprevention of keratinocyte carcinomas in organ transplant recipients, photoaging, acne vulgaris, and cutaneous infections including verrucae, onychomycosis, and cutaneous leishmaniasis. There is emerging evidence that photodynamic therapy plays a role in the management of actinic cheilitis, early-stage mycosis fungoides, extramammary Paget disease, lichen sclerosis, and folliculitis decalvans but there are no comparative studies with other active treatment modalities. Common barriers to topical photodynamic therapy include procedural pain, costs, and the time required for treatment delivery. There is significant heterogeneity in the photodynamic therapy protocols reported in the literature, including different photosensitizers, light sources, number of treatments, time between treatments, and use of procedural analgesia. Topical photodynamic therapy should be considered in the management of a spectrum of inflammatory, neoplastic, and infectious dermatoses. However, more comparative research is required to determine its role in the treatment algorithm for these dermatologic conditions and more methodological research is required to optimize photodynamic therapy protocols to improve the tolerability of the procedure for patients.

show abstract

Section: Folliculitis Decalvansmentioning

confidence: 85%

A Review of the Dermatologic Clinical Applications of Topical Photodynamic Therapy

Luo,

Bose,

Bawazir

et al. 2024

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…Photodynamic therapy demonstrated an immunemodulatory and antibacterial action, improved scar healing, anti-inflammatory properties, and can target fibroblasts, keratinocytes, sebaceous glands, and hair follicles. 8,9 Lin et al 8 reported FD stabilizing after 4 cycles of PDT at 2-week intervals. Their patient had received systemic antibiotics and isotretinoin for FD without improvement.…”

Section: Discussionmentioning

confidence: 99%

“…Lin et al 8 have also reported the utilization of photodynamic therapy with topical aminolevulinic acid in managing a recalcitrant FD in an adult 63‐year‐old male. Photodynamic therapy demonstrated an immune‐modulatory and antibacterial action, improved scar healing, anti‐inflammatory properties, and can target fibroblasts, keratinocytes, sebaceous glands, and hair follicles 8,9 . Lin et al 8 reported FD stabilizing after 4 cycles of PDT at 2‐week intervals.…”

Section: Discussionmentioning

confidence: 99%

Folliculitis decalvans managed with adalimumab: A case report

Alsantali,

Baghdadi,

Alghamdi

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…However, the therapeutic efficacy of PDT varies among different studies. Some patients experience favorable outcomes while others show no response or even worsening of symptoms [21][22][23][24].…”

Section: Photodynamic Therapy (Pdt)mentioning

confidence: 99%

Folliculitis Decalvans: A Review of Current Treatment Modalities

Krzesłowska,

Szewczyk,

Pytel

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Background: Folliculitis decalvans (FD) is a rare subtype of neutrophilic cicatricial alopecia, firstly described by Quinquad in 1888, as inflammatory scalp disease usually affecting young adults. The exact etiopathology of the disease is not fully understood, however the presence of Staphylococcus aureus, dysfunction of the host’s immune response, genetic factors, previous trauma of the scalp, as well as Epidermal Growth Factor Receptor inhibitors (EGFRi) use seem to play a role. Clinically, FD presents with scarring alopecic patches with follicular pustules, crusts and tufted hair. Objectives: As the full etiology of the disease is unknown and most data in the literature is based on retrospective date, therapeutic management is not precisely established. The objective of this review is to describe therapeutic options, as well as highlighting potential new therapeutic modalities reported in the literature. Limitations: Because FD is a rare disease, the main limitation is lack of randomized control trials, evaluating therapeutic modalities. Methods: An exhaustive search of references related to FD published in PubMed between 2017 and 2024 was undertaken, using the search term: "folliculitis decalvans". Articles with large patient cohorts and reviews were included, as well as case reports and case series, that reported novel treatment approaches for FD.Conclusions: The management of FD poses a challenge. Systemic antibiotics, particularly rifampicin and clindamycin, are considered the first-line agents and are commonly used in combination with local therapies. Systemic isotretinoin yields sustained remission in some cases, while biological agents exhibit promise in managing severe FD. Novel therapeutic modalities, incorporating, among others, botulinum toxin A injections, Platelet-Rich-Plasma (PRP), or surgical procedures, necessitate randomized double-blind trials to evaluate their safety and efficacy.

show abstract

Aminolevulinic acid photodynamic therapy for folliculitis decalvans: A case report

Cited by 5 publications

References 10 publications

A Review of the Dermatologic Clinical Applications of Topical Photodynamic Therapy

A Review of the Dermatologic Clinical Applications of Topical Photodynamic Therapy

Folliculitis decalvans managed with adalimumab: A case report

Folliculitis Decalvans: A Review of Current Treatment Modalities

Contact Info

Product

Resources

About